The spread of gram-negative antimicrobial resistance is driven by human, environmental, and other factors. Pranita D. Tamma, MD, reviews clinically important pathogens, mechanisms driving resistance, and strategies for treatment.
Read the Review Article “Gram-Negative Bacterial Resistance”: https://t.co/XCUH767k4m
#IDWeek2026 Next up What's Hot: Basic ID Science, papers over past year that are 'hot' and active.
Starting with Cefazolin inoculum effect paper, showing no diff in mortality with CZIE vs none, but microbiologic eradication was higher without.
(fingers hurt, going slower)
What is the optimal duration of antibiotics after ERCP decompression for cholangitis?
The #UEGWeek 2026 top abstract prize goes to Anouk Overdevest for her work on the COBRA trial, which shows that 1 day of antibiotic is non-inferior to 4-7 day courses 👏🏆
🔥 Brilliants minds debate oral fosfomycin for complicated UTI including pyelonephritis. With increasing ESBLs, we need options for UTI beyond cystitis. Oral fosfomycin is an appealing option, but is it ok for infection outside the bladder?
#pharmacist#MedEd
✅ Reciente publicación en The Lancet para recordar algo que es el Karma de los infectologos: la orina NO es estéril 🆘
Incluso destacan como el urobioma mantiene a raya a bacterias que de otra forma si serían patogenas. El Dx de ITU requiere SIEMPRE un contexto adecuado.
In a randomized trial involving adults who received local antibiotics during surgery for orthopedic infection, a short duration of systemic antibiotics was noninferior to a long duration regarding treatment failure at 12 months. Full SOLARIO trial results: https://t.co/4uIUCFkH1r
🔥Just published 🔥
Infective Endocarditis: Diagnosis, Antibiotic Therapy, and Management: A Scientific Statement From the American Heart Association #idxposts#IEWiki
https://t.co/0yXAfs4X6X
Thanks @Inox94
🚨 Can we treat Pneumocystis pneumonia without co-trimoxazole? In our study of 14 patients unable to receive standard therapy, echinocandin + clindamycin achieved clinical cure in 13/14. A promising alternative when TMP-SMX is not feasible.
https://t.co/qU2YWhv7ky
@ClinicaNavarra
🆕💥🔴Multicentre cohort(SAVE study)
Daptomycin or linezolid Vs vancomycin in the treatment of vancomycin-susceptible Enterococcus faecium bloodstream infections
Linezolid or daptomycin was not independently associated with treatment failure #idxposts
https://t.co/6KIgipc9Qw
🆕💥🟢Extending the Duration of Artemether-Lumefantrine Treatment for Uncomplicated Plasmodium falciparum Malaria to 5 days instead of 3 days : Updated US Centers for Disease Control and Prevention Guidance Based on Review of Surveillance, Consultations, and Published Data #idxposts https://t.co/wfYs2tSqRB
@PaulSaxMD Hard benefits in outpatients have been overstated and oversold too.
You get better about 17 hours faster. You trade that for ~ 1 in 6 chance for vomiting
Keep you out of hospital? Too small effect size to detect (if it even exists)
https://t.co/bpoSonC3Ym
SEPSIS 2026: Consenso internacional multidisciplinario, con 164 expertos de 22 países, establece 40 recomendaciones en siete áreas fundamentales del manejo de la sepsis. 🩺 https://t.co/VTSsEl6o1z @ClinicaNavarra
🆕🔥🟢Excellent review article
Carbapenemases: epidemiology, detection and management in a changing global landscape
🔺Carbapenemase classification.
🔺Characteristics of key carbapenemase families
🔺Geographic distribution
🔺Guideline-based treatment recommendations https://t.co/BeayHLiePW
Words matter!
It’s very frustrating that I’m still encountering the term “oral step-down” in major ID journals.
Let’s replace it with stewardship-aligned terms:
IV to oral switch
Oral transition or transitional therapy.
Streamlining
“Step-down” implies inferiority of oral antibiotics.
Time to stop using this term in ID journals—authors, editors, reviewers. #IDXposts
Wow—this is an amazing, comprehensive review! 🤩
They explore the origin and history behind the names of virtually every antibacterial and antifungal.
🆕🔥🟢 Review | #OFID
What’s in a Name? Etymology and History of Antibacterials and Antifungals
There are so many tables! 📚
I summarized them into 2 infographics 🦠🍄
Check it out! ✨👇 https://t.co/ixn75vkSoF
Nunca se había aleatorizado el oseltamivir en el paciente crítico con influenza.
REMAP-CAP acaba de hacerlo.
Y el resultado no solo es "no funciona": es probable que aumente la mortalidad a 90 días.
Hilo sobre un preprint que va a incomodar 🧵
1/15
Okay you Med Twitter cefadroxil-ites! The long awaited cohort study of cefadroxil for bacteremia (Including staph aureus!) with or without osteo is here! Have at it!
https://t.co/cmS0uY9fQg